SecBot SecBot
8-K ·Filed Nov 5, 2026

LXRX

LEXICON PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 19h ago SEC0001062822-26-000124
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor SONATA-HCM top-line results in Q1 2027 and the ZYNQUISTA NDA resubmission timeline; the cash runway of $183M supports operations into 2027 without near-term financing.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

LXRX drug pipeline →

ZYNQUISTA

◆ Mixed Named in this 8-K
Impact
Phase
Filed/Pre-NDA resubmission (already approved as Inpefa for heart failure)
Time to market
Uncertain. NDA resubmission expected Q4 2026; if accepted, FDA has up to 6 months to review a Class 2 resubmission, meaning a potential decision in mid-2027 at the earliest.
Next catalyst
None dated

What to watchWatch for Zynquista NDA resubmission announcement in Q4 2026, that event will signal whether Lexicon believes it has adequately addressed FDA concerns. Success would be a major de-risking event; failure or further delay would be a severe blow given the company's pipeline reliance on sotagliflozin. The ~41.6% implied upside to the analyst mean price target reflects the binary nature of this catalyst.

Price Chart

Loading chart...

Executive Summary

Lexicon reported Q3 2026 total revenue of $11.3M, down from $14.2M a year ago, driven by lower licensing/milestone revenue ($10.0M vs $13.2M). Net loss widened to $14.0M ($0.03 per share) from $12.8M ($0.04 per share). The company highlighted completion of SONATA-HCM enrollment (542 patients) and positive STENO1 safety data supporting a planned ZYNQUISTA NDA resubmission in Q1 2027.

Key Financial Metrics

EPS
−$0.03
est −$0.05 · +40.0%
Revenue
$11.3M
est $4.1M · +174.4% · -20.7% YoY
Rating
beat

Key Facts

  • Total revenue $11.3M vs $14.2M in Q3 2025, a 20.6% decline
  • Net loss $14.0M ($0.03 per share) vs $12.8M ($0.04 per share) in Q3 2025
  • Cash and investments $183.2M as of Sep 30, 2026, down from $190.6M at Jun 30, 2026
  • SONATA-HCM Phase 3 study enrolled 542 patients, top-line data expected Q1 2027
  • STENO1 safety data achieved FDA requirements for ZYNQUISTA NDA resubmission, planned Q1 2027
  • Earned third $10M milestone from Novo for LX9851 in August 2026, total $75M earned to date
  • FDA raised no objections to advancing pilavapadin into Phase 3 development

Financial Impact

Revenue decline of $2.9M YoY; net loss increased by $1.2M; cash burn of $7.4M in Q3

revenuenet losscash

Risk Factors

  • Revenue decline driven by lower milestone payments from Novo, which are lumpy and non-recurring
  • Net loss continues to widen as R&D and SG&A expenses remain elevated
  • Clinical trial risks for SONATA-HCM and ZYNQUISTA NDA resubmission

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001062822-26-000124
Document: lxrx-20261105.htm0001062822-26-000124
Document: 0001062822-26-000124-index-headers.html0001062822-26-000124
Document: 0001062822-26-000124-index.html0001062822-26-000124
Document: 0001062822-26-000124.txt0001062822-26-000124
8-K Data (Synthetic)0001062822-26-000124

Track record

16 reports on LXRX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
  5. Aug 6, 202614w ago 8-K Neutral 5/10 No price data
  6. Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
  7. Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
  8. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
  9. May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
  10. Apr 30, 202628w ago 8-K Bearish 6/10 Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026